Fred H. Hochberg
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Fred H. Hochberg has a total of 15 co-authors. Here are the top co-authors by number of shared publications:
- Andrew Chi
Alterome Therapeutics, San Diego, California
1 shared publication Christiana Toomey
MGH Cancer Center, Massachusetts General Hospital, Boston, MA, USA
1 shared publication- Deborah Anne Forst
Center for Tumors of the Nervous System and Pappas Center for Neuro-Oncology, Mass General Brigham Cancer Institute , Boston, Massachusetts
1 shared publication - Elizabeth R. Gerstner
Athinoula A. Martinos Center for Biomedical Imaging, Massachusetts General Hospital , Charlestown, Massachusetts
1 shared publication - Ephraim P. Hochberg
Center for Lymphoma, Massachusetts General Hospital Cancer Center, Boston, MA, USA
1 shared publication - Jeremy S. Abramson
Massachusetts General Hospital, Boston, MA
1 shared publication
Latest Publications
- Open Access
- 26 February 2018
- Published by Wiley in Journal of Extracellular Vesicles
- Vol. 7 (1) , 1438720
Extracellular vesicles: the growth as diagnostics and therapeutics; a survey
This article aims to document the growth in extracellular vesicle (EV) research. Here, we report the growth in EV‐related studies, patents, and grants as well as emerging companies with major intent on exosomes. Four different databases were utilized for electronic searches of published literature: two general databases – Scopus/Elsevier and Web of Science (WoS), as well as two specialized US government databases – the USA Patent and Trademark Office and National Institutes of Health (NIH) of the Department of Health and Human Services. The applied combination of key words was carefully chosen to cover the most commonly used terms in titles of publications, patents and grants dealing with conceptual areas of EVs. Within the time frame from 1 January 2000 to 31 December 2016, limited to articles published in English, we identified output using search strategies based upon Scopus/Elsevier and WoS, patent filings and NIH Federal Reports of funded grants. Consistently, USA and UK universities are the most frequent among the top 15 affiliations/organizations of the authors of the identified records. There is clear evidence of upward streaming of EV‐related publications. By documenting the growth of the EV field, we hope to encourage a roster of independent authorities skilled to provide peer review of manuscripts, evaluation of grant applications, support of foundation initiatives and corporate long‐term planning. It is important to encourage EV research to further identify biomarkers in diseases and allow for the development of adequate diagnostic tools that could distinguish disease subpopulations and enable personalized treatment of patients.
- 26 February 2018
- Published by Wiley in Journal of Extracellular Vesicles
- Vol. 7 (1) , 1438720
Open AccessExtracellular vesicles: the growth as diagnostics and therapeutics; a survey
This article aims to document the growth in extracellular vesicle (EV) research. Here, we report the growth in EV‐related studies, patents, and grants as well as emerging companies with major intent on exosomes. Four different databases were utilized for electronic searches of published literature: two general databases – Scopus/Elsevier and Web of Science (WoS), as well as two specialized US government databases – the USA Patent and Trademark Office and National Institutes of Health (NIH) of the Department of Health and Human Services. The applied combination of key words was carefully chosen to cover the most commonly used terms in titles of publications, patents and grants dealing with conceptual areas of EVs. Within the time frame from 1 January 2000 to 31 December 2016, limited to articles published in English, we identified output using search strategies based upon Scopus/Elsevier and WoS, patent filings and NIH Federal Reports of funded grants. Consistently, USA and UK universities are the most frequent among the top 15 affiliations/organizations of the authors of the identified records. There is clear evidence of upward streaming of EV‐related publications. By documenting the growth of the EV field, we hope to encourage a roster of independent authorities skilled to provide peer review of manuscripts, evaluation of grant applications, support of foundation initiatives and corporate long‐term planning. It is important to encourage EV research to further identify biomarkers in diseases and allow for the development of adequate diagnostic tools that could distinguish disease subpopulations and enable personalized treatment of patients.
- 12 February 2013
- Published by Wolters Kluwer Health in Neurology
- Vol. 80 (7_suppleme)
Methotrexate, Rituximab, Temozolomide (MRT) Induction Therapy for Elderly Patients with Primary Central Nervous System Lymphoma (PCNSL) (IN10-1.002)
- 12 February 2013
- Published by Wolters Kluwer Health in Neurology
- Vol. 80 (7_suppleme)
Methotrexate, Rituximab, Temozolomide (MRT) Induction Therapy for Elderly Patients with Primary Central Nervous System Lymphoma (PCNSL) (IN10-1.002)
- Open Access
- 20 November 2009
- Published by American Society of Hematology in Blood
- Vol. 114 (22) , 2496
Statin Use Improves Overall Survival and Time to Treatment Failure in Patients with Primary CNS Lymphoma.
Abstract 2496 Poster Board II-473
- 20 November 2009
- Published by American Society of Hematology in Blood
- Vol. 114 (22) , 2496
Open AccessStatin Use Improves Overall Survival and Time to Treatment Failure in Patients with Primary CNS Lymphoma.
Abstract 2496 Poster Board II-473